It’s something that I consider a core competency of the company -- we’re good at it,” D’Amelio said in an interview. “One of the nice things about Pfizer is we have the capacity to do any size deal that we want.”
...why would you post jobs and not hire anyone. Plus no news for sometime. Something has to be going on in the background that will be shocking either way very soon I suspect.
Assist in the design, execution and tracking of global clinical compliance plans
The Zika virus is transmitted by the bite of an infected Aedes aegypti mosquito – the same mosquito that transmits chikungunya and dengue. Zika is similar to dengue fever, and also has symptoms such as fever, joint and muscle pain, conjunctivitis, headache, weakness, rash, and swelling of the lower limbs. It was reported that symptoms may appear after three to 12 days of being bitten by an infected mosquito. The symptoms reportedly last for four to seven days; and no deaths have been reported due to the Zika virus.
By Holly Batterman, MD
Several months ago, doctors from the Global Virus Network questioned whether the United States was ready for the next viral disease threat. Referencing the mosquito-borne virus chikungunya – and noting that it was headed to the United States — the researchers concluded: “This article may have been the first occasion where you’ve seen the word ‘chikungunya.’ But it most assuredly won’t be the last.”[i]
The outbreak in South Korea has been spreading at an unusually fast pace, with 138 confirmed infections as of Saturday, with the country's first case diagnosed on May 20.
South Korea on Saturday reported the 14th death from the disease and 12 new cases, including that of an ambulance driver who transported a patient infected with the deadly virus
San Diego & Plymouth Meeting
1) Senior Manufacturing Engineer II
2) Associate Director of Data Management
3) Research Assistant I
4) Clinical Program Manager
5) Electrical Test Technician II
7) IT Site Support
8) Product Development Scientist
9) IT Site Manager (2)
10) IT Co-op Intern
11) Research Associate II
12) Research Associate II Oncology Immunotherapy
13) Senior Mechanical Engineer
Fear is beginning to take hold in South Korea, as the MERS outbreak weaves its way throughout the country. There have now been four confirmed deaths and 41 people diagnosed with the virus.
BLUE BELL, Pa., May 27, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its novel DNA-based therapeutic monoclonal antibody targeting Chikungunya virus (CHIKV) completely protected mice from a lethal CHIKV challenge. In this preclinical study, a prototype DNA plasmid construct encoding for a monoclonal antibody for CHIKV envelope protein was created using Inovio's patented DNA optimization technology and delivered with its CELLECTRA® device. The results were presented as a poster at the 17th Annual Meeting of the American Society of Gene & Cell Therapy in Washington, DC.
Chikungunya virus (CHIKV) has re-emerged as a serious mosquito-borne alpha-virus responsible for several recent epidemics in tropical Africa and Asia. Recent evidence suggests that CHIKV, which is primarily transmitted to humans from mosquitoes, could spread to other parts of the world. There is no vaccine or therapeutic against this virus.
In this presented study, Inovio scientists and collaborators developed a novel DNA plasmid encoding a highly engineered immunoglobulin encoding a CHIKV monoclonal antibody (mAb) to directly generate in vivo production of an anti-CHIKV mAb in mice. They demonstrated that the serum of transfected animals exhibited the specific ability to bind to the CHIKV envelope antigen and this serum possessed CHIKV-neutralizing activity. Importantly, the treatment of the animals with anti-CHIKV mAb plasmids protected 100% of the treated animals from a lethal injection of CHIKV virus while 100% of the control animals died. The treated animals were also spared of virus-related morbidity, as measured by dramatic weight loss and lethargy.
Monoclonal antibodies (mAb) were a transformational scientific innovation designed to enhance the immune system's ability to regulate cell functions. They are designed to bind to a very specific epitope (area) of an antigen or cell surface target and can bind to almost any selected target. mAbs have the unique ability to alert the immune system to attack and kill specific cancer cells (as in the case of Yervoy®) or block certain biochemical pathways (such as those leading to rheumatoid arthritis, as in the case of Remicade®). However, mAb technology has limitations. Delivered by passive administration, meaning they are manufactured outside the body, mAbs typically require costly large-scale laboratory development and production. Additional limitations include the necessity for repeat administrations and their limited duration of in vivo potency.
The paradigm shift of Inovio's technology is that the DNA for a monoclonal antibody is encoded in a DNA plasmid, delivered directly into cells of the body using electroporation, and the mAbs are "manufactured" by these cells. Using this patent-protected approach, Inovio previously published that a single administration of a highly optimized DNA-based monoclonal antibody targeting HIV virus in mice generated antibody molecules in the bloodstream possessing desirable functional activity including high antigen-binding and HIV-neutralization capabilities against diverse strains of HIV viruses. This new work further demonstrates the capability of this technology using a CHIKV challenge model.
Unsuspecting U.S. Travelers Bring Novel Disease Home, And It Spreads
by Maryn McKenna
When a disease threat looms, you might expect that everyday people won’t recognize the danger, but professionals will. That isn’t always the case, though. Some data made public last week demonstrates that even people well-informed about risks can be vulnerable—and underlines the threat that one new disease poses to the United States.
Between December 2013 and March 2015, more than 1.2 million cases of chikungunya have been reported in 44 countries and territories throughout the Americas. Local transmission has been reported from almost every island in the Caribbean, all countries in Central America, several countries in South America, and parts of Mexico. In 2014, nearly 2500 cases of chikungunya were reported in the United States. Almost all were in returning travelers, with the exception of 11 locally transmitted cases in South Florida. The situation is likely to change.
To date, Malaysia has seen 40,007 dengue fever cases with 23,376 cases reported from Selangor state alone.
In the Americas, 12,445 additional chikungunya cases have been reported in the Western hemisphere with 10,000 of the new cases being reported from Colombia (new total of more than 285,000 cases).
In Mexico, the number of confirmed chikungunya cases is now at 906, increasing by 228 cases in the past two epidemiological weeks